The Quantellect read.As of Nov 19, 2026, 8 active firms cover Genmab AS: 7 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $32.00 to $58.00, a moderate spread. The average target of $42.94 sits 16% below the current $50.97. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.30 next quarter toward $1.73 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy788%
Neutral113%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$42.94
-15.8% downside
Average target across 8 active firms as of Nov 19, 2026 vs $50.97 current
Highest Target$58.00
Average Target$42.94
Lowest Target$32.00
Detailed analyst forecasts for GMAB
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 7 of 8 active firms rate GMAB a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GMAB EPS & revenue forecast
EPS · NEXT QUARTER
$0.30
Range $0.30 – $0.31 · 2 analysts · +267% YoY
Next period, 2 analysts expect Genmab AS to earn $0.30 a share (range $0.30 – $0.31), versus $0.08 a year earlier. Full-year consensus is $1.26, growing to $1.73 the year after.
REVENUE · NEXT QUARTER
$7.2B
Range $6.8B – $7.7B · 2 analysts · +26% YoY
Revenue is expected to reach $7.2B (range $6.8B – $7.7B), +26.4% year-over-year. Full-year consensus is $30.0B, rising to $36.3B next year.
Top analysts covering Genmab AS
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GMAB.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$80.00+57.0% to target
Overall win rate
53%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$50.00-1.9% to target
Overall win rate
36%
+ Follow
#3
MP
Matt Phipps
William Blair
Buy
No targeton GMAB
Coverage
—
+ Follow
#4
Asthika Goonewardene
Truist Securities
Buy
$45.00-11.7% to target
Coverage
—
+ Follow
#5
Yaron Werber
TD Cowen
Buy
$52.00+2.0% to target
Coverage
—
+ Follow
GMAB stock forecast FAQ
What is GMAB's average 12-month price target?+
The 8 active firms with a live target average $42.94 for Genmab AS over the next 12 months, ranging from a $58.00 high to a $32.00 low, as of Nov 19, 2026.
Is GMAB stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for GMAB?+
The Street-high target is $58.00 (Guggenheim), and the Street-low is $32.00 (Wolfe Research). The average of all 8 active-firm targets is $42.94.
How many active Wall Street firms cover GMAB?+
8 active firms have a recognized rating on Genmab AS as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering GMAB?+
Among analysts who currently cover GMAB, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $80.00 target.
What is Genmab AS's projected EPS for next quarter?+
The consensus estimate is $0.30 per share (range $0.30 – $0.31) across 2 analysts. Full-year EPS is projected at $1.26, rising to $1.73 the following year.
How much revenue is Genmab AS expected to report next quarter?+
Consensus revenue is $7.2B (range $6.8B – $7.7B). Full-year revenue is projected at $30.0B, growing to $36.3B next year.
Have analysts been upgrading or downgrading GMAB lately?+
As of Nov 19, 2026, 7 of 8 active firms rate GMAB a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GMAB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.